How depression and antidepressant drugs work

May 18, 2016 by Sam Sholtis
How depression and antidepressant drugs work
Mutations in the GABA-A receptor cause a temporary imbalance between  GABA signaling (yellow) and glutamate signaling (blue) in the brain.  Homeostatic down regulation of glutamate signaling rebalances the system  at a lower level and can lead to depression. Treatment with ketamine  restores both GABA and glutamate levels to normal. Credit: Penn State

New research demonstrates the effectiveness of ketamine to treat depression in a mouse model of the disease and brings together two hypotheses for the cause of depression. The research, led by Bernhard Lüscher, professor of biology and of biochemistry and molecular biology at Penn State University, is in press and will be published in the September 15, 2016, print edition of the journal Biological Psychiatry.

"Depression is the second most expensive health problem that we face worldwide, but this fact is not very well known because there is a stigma attached to depression and people don't like to talk about it," said Lüscher. "About 17 percent of Americans will be treated for depression at some point in their lives, but there are limited treatment options and about one-third of patients do not respond to these treatments."

Lüscher and his colleagues generated a for depression by introducing a mutation into a gene that codes for one of the subunits of a receptor for GABA—the second most abundant chemical used by nerve cells in the brain to communicate. GABA functions mainly to reduce the activity of nerve cells. The receptor mutation results in a reduction in GABA signaling of about 15 to 20 percent and mimics reductions in GABA signaling seen in patients with depression. The that have the mutation exhibit traits associated with depression, such as reduced pleasure seeking, and they become normal again following treatment with antidepressant medications.

"You can think of GABA as acting like the brakes of a car—its function is to slow activity in nerve cells," said Lüscher. "Its counterpart is glutamate, another signaling chemical in the brain that acts as the accelerator of nerve-cell activity. When we reduced the function of GABA in our mice, we were surprised to see that the level of glutamate was also reduced. This result suggests that the brain has mechanisms that maintain a balance between the brakes and the accelerator to prevent brain activity from going out of control, a state we refer to as homeostasis."

The researchers treated the mice with low doses of ketamine, an experimental antidepressant drug known to act by transiently blocking a major class of glutamate receptors in . "Treatment with ketamine not only normalized the behavior and brought glutamate receptor levels back up to normal in our mice, but GABA function also was restored," said Lüscher. Importantly, the effects of ketamine were only observed in mice with the receptor mutation where nerve signaling was defective, and not in normal mice. "Our results bring together the hypothesis that depression results from deficits in GABA signaling and the hypothesis that depression results from deficits in glutamate signaling. We showed that the -like behavior in our mice results from the reduction of both GABA and glutamate, and importantly, that both can be restored with a single dose of ketamine."

The researchers plan to use their mouse model to better understand how ketamine functions to develop safer alternatives. "Ketamine has many advantages over currently used ," said Lüscher. "It acts quickly and has long lasting effects, but it is addictive and can induce psychosis, so we hope to use our model to better understand how ketamine works biochemically. We can then begin to develop -like drugs without the unwanted side effects."

Explore further: Ketamine lifts depression via a byproduct of its metabolism

More information: Zhen Ren et al. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment, Biological Psychiatry (2016). DOI: 10.1016/j.biopsych.2016.02.009

Related Stories

Ketamine lifts depression via a byproduct of its metabolism

May 4, 2016
A chemical byproduct, or metabolite, created as the body breaks down ketamine likely holds the secret to its rapid antidepressant action, National Institutes of Health (NIH) scientists and grantees have discovered. This metabolite ...

Study offers insight on how a new class of antidepressants works

September 30, 2015
A new class of drugs under development to treat depression has shown some success by targeting brain cells' ability to respond to the chemical messenger glutamate. But the mechanism by which these experimental therapies work ...

Intravenous ketamine may rapidly reduce suicidal thinking in depressed patients

May 10, 2016
Repeat intravenous treatment with low doses of the anesthetic drug ketamine quickly reduced suicidal thoughts in a small group of patients with treatment-resistant depression. In their report receiving Online First publication ...

Would an 'anti-ketamine' also treat depression?

November 18, 2013
Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. ...

Team IDs brain circuit involved in party drug's antidepressant effect

December 21, 2015
At its best, the drug ketamine relieves depression within two hours and its beneficial effect on patients may last a week. At its worst, ketamine, the party drug "Special K," is addictive and may send recreational users into ...

Recommended for you

Before assigning responsibility, our minds simulate alternative outcomes, study shows

October 17, 2017
How do people assign a cause to events they witness? Some philosophers have suggested that people determine responsibility for a particular outcome by imagining what would have happened if a suspected cause had not intervened.

For older adults, volunteering could improve brain function

October 17, 2017
Older adults worried about losing their cognitive functions could consider volunteering as a potential boost, according to a University of Missouri researcher. While volunteering and its associations with physical health ...

Magic mushrooms may 'reset' the brains of depressed patients

October 13, 2017
Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity.

Living near a forest keeps your amygdala healthier

October 13, 2017
A study conducted at the Max Planck Institute for Human Development has investigated the relationship between the availability of nature near city dwellers' homes and their brain health. Its findings are relevant for urban ...

Scientists researching drugs that could improve brain function in people with schizophrenia

October 12, 2017
Virginia Commonwealth University researchers are testing if drugs known as HDAC inhibitors improve cognition in patients with schizophrenia who have been treated with the antipsychotic drug clozapine.

Researchers find a fine timeline between delusion and reality

October 12, 2017
The line between reality and delusion may be just a matter of time, a new Yale study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.